Successful treatment of advanced squamous cell carcinoma arising from mature cystic teratoma of the ovary with homologous recombination deficiency: A case report.

Bevacizumab Homologous recombination deficiency Mature cystic teratoma Olaparib Platinum-based chemotherapy Squamous cell carcinoma

Journal

International journal of surgery case reports
ISSN: 2210-2612
Titre abrégé: Int J Surg Case Rep
Pays: Netherlands
ID NLM: 101529872

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 09 04 2023
revised: 12 05 2023
accepted: 14 05 2023
medline: 22 5 2023
pubmed: 22 5 2023
entrez: 22 5 2023
Statut: ppublish

Résumé

Squamous cell carcinoma (SCC) arising from mature cystic teratoma of the ovary (MCT-SCC) has a poor prognosis at advanced stages. Although the relationship between homologous recombination deficiency (HRD) and platinum-based chemotherapy sensitivity or poly (ADP ribose) polymerase (PARP) inhibitor efficacy in epithelial ovarian cancer has been demonstrated in clinical trials, the significance of HRD status in MCT-SCC has not previously been described. A 73-year-old woman underwent emergency laparotomy due to ovarian tumor rupture. The ovarian tumor was strongly adherent to the surrounding pelvic organs and could not be completely resected. The postoperative diagnosis was stage IIIB MCT-SCC (pT3bNXM0) of the left ovary. After surgery, we conducted the myChoice CDx. The genomic instability (GI) score of 87 was remarkably high, and there was no BRCA1/2 pathogenic mutation. After six courses of combination therapy with paclitaxel and carboplatin, the residual tumors had shrunk by 73 %. We performed interval debulking surgery (IDS), and the residual tumors were completely resected. Subsequently, the patient underwent two courses of the combination of paclitaxel, carboplatin, and bevacizumab, followed by maintenance therapy with olaparib and bevacizumab. Twelve months after IDS, no recurrence has been observed. The present case suggests that there are some HRD cases among MCT-SCC patients and that IDS and maintenance therapy with PARP inhibitors may be effective in such cases, as in epithelial ovarian cancer. Although the frequency of HRD-positive status in MCT-SCC remains unknown, HRD testing may provide appropriate treatment options for advanced MCT-SCC.

Identifiants

pubmed: 37216734
pii: S2210-2612(23)00458-3
doi: 10.1016/j.ijscr.2023.108329
pmc: PMC10213303
pii:
doi:

Types de publication

Case Reports

Langues

eng

Pagination

108329

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Ryo Tamura (R)

Department of Gynecology, Niigata Cancer Center Hospital, Niigata, Japan; Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Japan. Electronic address: ryo-h19@niigata-cc.jp.

Masayuki Yamaguchi (M)

Department of Gynecology, Niigata Cancer Center Hospital, Niigata, Japan.

Yohei Kitani (Y)

Department of Gynecology, Niigata Cancer Center Hospital, Niigata, Japan.

Nobumichi Nishikawa (N)

Department of Gynecology, Niigata Cancer Center Hospital, Niigata, Japan.

Takashi Kawasaki (T)

Department of Pathology, Niigata Cancer Center Hospital, Niigata, Japan.

Akira Kikuchi (A)

Department of Gynecology, Niigata Cancer Center Hospital, Niigata, Japan.

Classifications MeSH